Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 5183686, 9 pages
http://dx.doi.org/10.1155/2016/5183686
Clinical Study

The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus Manifestation

1Department of Microbiology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China
2West China School of Public Health, No. 4 West China Teaching Hospital, Sichuan University, Chengdu, China
3Department of Rheumatology, Jinjiang District People’s Hospital of Chengdu City, Chengdu, China
4ICU, West China Hospital, Sichuan University, Chengdu, China

Received 12 June 2016; Revised 2 September 2016; Accepted 8 September 2016

Academic Editor: Selena Vigano

Copyright © 2016 Liuye Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Ginzler and J. Tayar, Fast facts of Lupus, 2015, http://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Lupus.
  2. Z. Amoura, C. Deligny, J.-L. Pennaforte et al., “Cost of systemic lupus erythematorus for adult patients with active and treated disease in France (LUCIE study),” Revue de Medecine Interne, vol. 35, no. 11, pp. 700–708, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. A. E. Clarke, M. B. Urowitz, N. Monga, and J. G. Hanly, “Costs associated with severe and nonsevere systemic lupus erythematosus in Canada,” Arthritis Care and Research, vol. 67, no. 3, pp. 431–436, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Leszczyński and K. Pawlak-Buś, “New treatment strategy including biological agents in patients with systemic lupus erythematosus,” Polskie Archiwum Medycyny Wewnętrznej, vol. 123, no. 9, pp. 482–490, 2013. View at Google Scholar · View at Scopus
  5. D. Gumber, J. Paul, and P. Ranganathan, “Clinical trials in systemic lupus erythematosus: a status report on ongoing trials,” Rheumatology International, vol. 34, no. 12, pp. 1633–1638, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Leone, S. Sciascia, A. Kamal, and M. Khamashta, “Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies,” Expert Review of Clinical Immunology, vol. 11, no. 1, pp. 109–116, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. J. T. Merrill, C. M. Neuwelt, D. J. Wallace et al., “Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial,” Arthritis and Rheumatism, vol. 62, no. 1, pp. 222–233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. T. Merrill, J. P. Buyon, R. A. Furie et al., “Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER),” Lupus, vol. 20, no. 7, pp. 709–716, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. B. H. Rovin, R. Furie, K. Latinis et al., “Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study,” Arthritis and rheumatism, vol. 64, no. 4, pp. 1215–1226, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. V. Navarra, R. M. Guzmán, A. E. Gallacher et al., “Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial,” The Lancet, vol. 377, no. 9767, pp. 721–731, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Furie, M. Petri, O. Zamani et al., “A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 63, no. 12, pp. 3918–3930, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Sthoeger, A. Sharabi, and E. Mozes, “Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus,” Journal of Autoimmunity, vol. 54, pp. 60–71, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Huang, H. Wu, and Q. Lu, “The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review,” Clinical Reviews in Allergy and Immunology, vol. 47, no. 2, pp. 219–233, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Ben-Nun, H. Wekerle, and I. R. Cohen, “Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein,” Nature, vol. 292, no. 5818, pp. 60–61, 1981. View at Publisher · View at Google Scholar · View at Scopus
  15. Z.-G. Li, R. Mu, Z.-P. Dai, and X.-M. Gao, “T cell vaccination in systemic lupus erythematosus with autologous activated T cells,” Lupus, vol. 14, no. 11, pp. 884–889, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Chen, N. Li, Y. C. Q. Zang et al., “Vaccination with selected synovial T cells in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 56, no. 2, pp. 453–463, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Z. Zhang, V. M. Rivera, M. V. Tejada-Simon et al., “T cell vaccination in multiple sclerosis: results of a preliminary study,” Journal of Neurology, vol. 249, no. 2, pp. 212–218, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Ivanova, G. Seledtsova, S. Mamaev, A. Shishkov, and V. Seledtsov, “Immune responses induced by T-cell vaccination in patients with rheumatoid arthritis,” Human Vaccines and Immunotherapeutics, vol. 10, no. 5, pp. 1221–1227, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. W. J. Crinnion, “Sauna as a valuable clinical tool for cardiovascular, autoimmune, toxicant induced and other chronic health problems,” Alternative Environmental Medicine Review, vol. 16, no. 3, pp. 215–255, 2011. View at Google Scholar
  20. W. Siems, N. Bresgen, R. Brenke et al., “Pain and mobility improvement and MDA plasma levels in degenerative osteoarthritis, low back pain, and rheumatoid arthritis after infrared A-irradiation,” Acta Biochimica Polonica, vol. 57, no. 3, pp. 313–319, 2010. View at Google Scholar · View at Scopus
  21. D. D. Gladman, D. Ibañez, and M. B. Urowltz, “Systemic lupus erythematosus disease activity index 2000,” The Journal of Rheumatology, vol. 29, no. 2, pp. 288–291, 2002. View at Google Scholar · View at Scopus
  22. A. Mak and N. Y. Kow, “The pathology of T cells in systemic lupus erythematosus,” Journal of Immunology Research, vol. 2014, Article ID 419029, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Liao, C. Chang, H. Wu, and Q. Lu, “Cell-based therapies for systemic lupus erythematosus,” Autoimmunity Reviews, vol. 14, no. 1, pp. 43–48, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. Q. Lu, J. Zhang, D. Deng et al., Lupus: From Bench to Bedside, Peking University Medical Press, Beijing, China, 2012.
  25. M. Chen, M. R. Daha, and C. G. M. Kallenberg, “The complement system in systemic autoimmune disease,” Journal of Autoimmunity, vol. 34, no. 3, pp. J276–J286, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Truedsson, “Classical pathway deficiencies—a short analytical review,” Molecular Immunology, vol. 68, no. 1, pp. 14–19, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. A.-M. Orbai, L. Truedsson, G. Sturfelt et al., “Anti-C1q antibodies in systemic lupus erythematosus,” Lupus, vol. 24, no. 1, pp. 42–49, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. V. V. Vasilev, R. Noe, M.-A. Dragon-Durey et al., “Functional characterization of autoantibodies against complement component C3 in patients with lupus nephritis,” Journal of Biological Chemistry, vol. 290, no. 42, pp. 25343–25355, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Fabbri, R. Fuller, E. Bonfá, L. K. N. Guedes, P. S. R. D'Alleva, and E. F. Borba, “Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy,” Clinical Rheumatology, vol. 33, no. 4, pp. 505–509, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Thamer, M. A. Hernán, Y. Zhang, D. Cotter, and M. Petri, “Prednisone, lupus activity, and permanent organ damage,” Journal of Rheumatology, vol. 36, no. 3, pp. 560–564, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Murphy, L. Lisnevskaia, and D. Isenberg, “Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment,” The Lancet, vol. 382, no. 9894, pp. 809–818, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. I. Ruiz-Arruza, C. Barbosa, A. Ugarte, and G. Ruiz-Irastorza, “Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis,” Autoimmunity Reviews, vol. 14, no. 10, pp. 875–879, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. S.-Y. Chen, C.-B. Choi, Q. Li et al., “Glucocorticoid use in patients with systemic lupus erythematosus: association between dose and health care utilization and costs,” Arthritis Care & Research, vol. 67, no. 8, pp. 1086–1094, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Karussis, H. Shor, J. Yachnin et al., “T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial,” PLoS ONE, vol. 7, no. 12, article e50478, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. M. W. P. Tsang-A-Sjoe and I. E. M. Bultink, “Systemic lupus erythematosus: review of synthetic drugs,” Expert Opinion on Pharmacotherapy, vol. 16, no. 18, pp. 2793–2806, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Doria, L. Iaccarino, G. La Montagna et al., “Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy,” Clinical & Experimental Rheumatology, vol. 33, no. 3, pp. 375–384, 2015. View at Google Scholar · View at Scopus